Psychedelics research gains support from the Trump administration for treating PTSD and mental health conditions, with Veterans Affairs exploring treatments that show promise in clinical trials.

Administered intravenously, the monoclonal antibody MK-2060 has a "novel approach" to anticoagulation by blocking the ...

Abstract Title: Rationale and Study Design for a Phase 2/3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Novocure NVCR recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating ...

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.